News | April 26, 2024
Divi's Laboratories to expand capacity at an outlay of approx. Rs. 700 Cr
The proposed facility is expected to be operational around January, 2027
The proposed facility is expected to be operational around January, 2027
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
Laurus Labs has reported total income of Rs. 1,458.20 crores during the period ended March 31, 2024
Sales reflect continued strong growth in oncology and vaccines
Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024
The company will closely work with the USFDA to address and respond to the observations in an expeditious manner
One form of thalidomide has the intended sedative effect but the opposite mirror-image form interferes with foetal development
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
Open a printable version of this pageEmail the URL of this page to a friend
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
